Marex Group’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Marex Group's VRDN Position: Q3 2026 in Review
Marex Group opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 12,000 shares worth $247K. The stake represents ﹤0.01% of the portfolio and ranks #1459 among its holdings.
235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Marex Group held 12,000 shares of Viridian Therapeutics worth $247K as of Q3 2026.
- Viridian Therapeutics was a new Marex Group position in Q3 2026.
- Viridian Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q3 2026, its #1459 holding.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Marex Group's 13F filing for Q3 2026, filed 16 Nov 2026.